GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » PE Ratio (TTM)

KZIA (Kazia Therapeutics) PE Ratio (TTM) : At Loss (As of Dec. 15, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-15), Kazia Therapeutics's share price is $3.55. Kazia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.77. Therefore, Kazia Therapeutics's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Kazia Therapeutics's PE Ratio (TTM) or its related term are showing as below:

KZIA' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 12.79   Max: 15.36
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of Kazia Therapeutics was 15.36. The lowest was 0.00. And the median was 12.79.


KZIA's PE Ratio (TTM) is ranked worse than
100% of 246 companies
in the Biotechnology industry
Industry Median: 27.14 vs KZIA: At Loss

Kazia Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was $-4.30. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.77.

As of today (2024-12-15), Kazia Therapeutics's share price is $3.55. Kazia Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.79. Therefore, Kazia Therapeutics's PE Ratio without NRI for today is At Loss.

Kazia Therapeutics's EPS without NRI for the six months ended in Jun. 2024 was $-4.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.79.

During the past 3 years, the average EPS without NRI Growth Rate was -20.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.50% per year.

During the past 13 years, Kazia Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 65.30% per year. The lowest was -86.60% per year. And the median was 7.80% per year.

Kazia Therapeutics's EPS (Basic) for the six months ended in Jun. 2024 was $-4.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.77.


Kazia Therapeutics PE Ratio (TTM) Historical Data

The historical data trend for Kazia Therapeutics's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics PE Ratio (TTM) Chart

Kazia Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Kazia Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Kazia Therapeutics's PE Ratio (TTM)

For the Biotechnology subindustry, Kazia Therapeutics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's PE Ratio (TTM) falls into.



Kazia Therapeutics PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Kazia Therapeutics's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=3.55/-6.766
=At Loss

Kazia Therapeutics's Share Price of today is $3.55.
For company reported semi-annually, Kazia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.77.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Kazia Therapeutics  (NAS:KZIA) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Kazia Therapeutics PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204